IABCR Journal Header

Article Viewer

Search

Article QR Code

REVIEW ARTICLE

10.21276/iabcr.2017.3.1.2
Alopecia Areata – A literature Review
Download PDF     Print

January - March 2017 | Vol 3 | Issue 1 | Page : 7-10

S Mushtaq 1*, Md. Raihan2, Azad Lone3, Mushtaq M4

1M.D. Scholar, Jamia Hamdard, Hamdard University, New Delhi;
2Assistant Professor, Department of Dermatology, Rama Medical College Delhi;
3Medical Officer, ISM department, Govt. of Jammu and Kashmir;
4Medical Officer, L.D Hospital, Govt. of Jammu and Kashmir.

How to cite this article: : Mushtaq S, Raihan Md., Lone A, Mushtaq M. Alopecia Areata – A literature Review. Int Arch BioMed Clin Res. 2017;3(1):7-10.DOI:10.21276/iabcr.2017.3.1.2

ABSTRACT

Alopecia areata (AA) is a disease marked by extreme variability in hair loss, not only at the time of initial onset of hair loss but in the duration, extent and pattern of hair loss during any given episode. This variable and unpredictable nature of spontaneous re-growth and lack of a uniform response to various therapies has made clinical trials in alopecia areata difficult to plan and implement. It is a type of alopecia that affects males and females equally. It occurs in both children and adults. The peak age of occurrence is 20 to 50 years .The most common clinical presentation is asymptomatic shedding of telogen hairs followed by patchy non scarring hair loss in association with nail pitting, Beau’s line and nail dystrophy. The disease may progress from this limited presentation to total loss of all scalp hairs (Alopecia totalis) or all body hair (alopecia universalis) with significant onychodystrophy. Mostly it is characterised by reversible hair loss involving the scalp although others areas of head including eyelashes, eyebrows and beard may also be affected. Although, it is a mostly cosmetic problem but it often has devastating effects on quality of life and self-esteem. The paper aims at providing an overview of Alopecia areata.

Keywords: Alopecia areata, totalis, universalis, onchodystrophy, telogen

REFERENCES
  1. Messenger AG, de Berker DAR, Sinclair RB. Disorders of hair. In: Burns T, Breathnach S, Cox N, Griffiths C (Editors). Rook`s textbook of Dermatology. Vol.4. 8th ed. Singapore: Blackwell Publishing Ltd; 2010; 66.31-32.
  2. Rebora A. Acute diffuse and total Alopecia of female scalp: A new subtype of diffuse alopecia areata that has a favourable prognosis- a reply. Dermatology 2003;207(3):339
  3. Garnacho-Saucedo GM, Salido-Vallejo R, Alvarez-López MÁ, Casas de la Asunción E, Ruano-Ruiz J, García-Nieto AV et al. Renbok phenomenon in a patient With Alopecia Areata Universalis. Arch Dermatol 2012;148:964-5
  4. Braunwald, Fauci, Kasper, Hauser, Longo, Jameson. Harrison`s principle of internal medicine. 15th ed., Vol.1. USA: MCGrawhill companies; 2001: 316.
  5. Tsuruta D, Hayashi A, Kobayashi H, Nakogowa K, Furukawa M, Ishii M. Psuedocyst of the scalp. Dermatology 2005; 210:333-335.
  6. Sharma VK. Pulsed administration of corticosteroids in the treatment of alopecia Areata. Int J Dermatol 1996; 35:133-6.
  7. Hertl M. Autoimmune disease of the skin. Pathogenesis, diagnosis, management. 3rded. new York: Springer wien.2005.463-95.
  8. Friedli A ,Labarthe MP, Engelhardt E, Feldmann R, Salomon D, Saurat JH. Pulse Methylpredisolone therapy for alopecia areata; an open prospective study of 45 patients. J Am Acad Dermatol 1998; 39:597-602.
  9. Jackow C, Piffer N, Hordinsky M, Nelson J, Tarrand J, Duvic M. Alopecia areata and cytomegalovirus infection in twins; genes versus environment. J Am Acad Dermatol 1998; 38:418- 425.
  10. Colombe BW, Price VH, Khoury EL, Garovoy MR, Lou CD. HLA class II antigen associations help to define two types of alopecia areata. J Am Acad dermatol 1995; 33: 757-764.
  11. Tosti A, Guerra L, Bardazzi F. Contact Urticaria during topical immunotherapy. Contact Dermatitis 1989; 21:196-7.
  12. Hoffmann R, Wenzel E, Huth A van der Steen P, Schäufele M, König A, Happle R. Growth factor m RNA levels in Alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. Acta Derm Venereol 1996;76:17-20.
  13. Galbraith GMP, Thiers BH, Vasily DB, Fudenberg HH. Immunological profiles in alopecia areata. Br J Dermatol. 1984;110:163-70.
  14. Muller SA, Winkelmann RK. Alopecia areata; an evaluation of 736 patients. Arch Dermatol 1963; 88: 290-7.
  15. Diseases of the skin appendages In: Odom RB James WD, Berger TG, eds. Andrews’disease of the skin, clinical dermatology, 9th edition Philadelphia: WB Suanders Company,2000;943-990.
  16. Brown WH. The aetiology of alopecia areata and its relationship to vitiligo and possibly scleroderma. Br J Dermatol 1979; 41: 299.
  17. Wygledowska-Kania M, Bogdanowski T. Psychic factors in case histories of patients with alopecia areata –preliminary report. Psychiatry Pol 1996;30:669-76.
  18. Kumar S. VK thesis a study of Clinical Patterns, Etiological And Predisposing Factors And Associated Disease In Patients With Focal Non-Scarring Alopecia(Excluding Androgenetic Alopecia).2001-2004:15,18,19,24,27
  19. Taisuke ITO, Tokura Y. Alopecia areata triggered or exacerbated by swine flu virus infection. J Dermatol 2012; 39:863-4.
  20. Elder D.E, Elenitsas R, Bernett L, Johnson, Murphy G.F., Xiaowei Xu. Lever’s Histopathology of The skin. 10th ed., China: Lippincott Williams & Wilkins.; 2009:473,474,475
  21. Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med 2012;366:1515-25.
  22. Hunter JAA, Savin JA, Dahl MV. Clinical dermatology. 3rd ed. USA: Blackwell publication limited; 2002; 164.
  23. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol 2000; 42:549-566

Published by Ibn Sina Academy of Medieval Medicine & Sciences, registered in 2001 under Indian Trusts Act, 1882.
Publication Manager: Dr. Tayyaba Farhan
Index Copernicus